PINAS LUMAGDA NG KASUNDUAN PARA MAKAKUHA NG 30M DOSES NG COVOVAX VACCINE

Ni Raiza F. Cabugwang
Photo courtesy of pna.gov.ph
Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

Nilagdaan na ni Vaccine Czar Secretary Carlito Galvez, Jr. at ng Serum Institute of India (SII) at Faberco Life Sciences, Inc. noong Enero 9, 2021 ang kasunduan upang masiguro ng bansa ang suplay ng 30 milyong doses ng COVID-19 vaccine na Covovax.

Inaasahang maipamamahagi ang naturang bakuna sa third quarter ng taong ito.

“This is a significant milestone in relations between India and the Philippines. It shows that we don’t have to look far beyond Philippine shores to find friends who are willing to help each other out,” pahayag ni Faberco Life Sciences Inc. founder Kishore Hemlani. 

Nakipag-ugnayan ang SII, na siyang pinakamalaking vaccine manufacturer sa buong mundo, sa Novavax, isang US-based biotechnology company, upang mabuo at maipagbili ang Covovax vaccine.

“The vaccine will be used to vaccinate 15 million vulnerable and poor Filipinos. The vaccine is stable at 2°C to 8°C, the standard temperature that is within the existing cold chain system in the Philippines, thus allowing its distribution to the remotest barangays,” paliwanag ni Faberco Life Sciences Medical Director Dr. Luningning Villa.

Kasalukuyang isinasagawa ang ikatlong stage ng trial ng nasabing bakuna sa United Kingdom, Estados Unidos, at Mexico.

Inaasahang mapagpapasyahan na ang presyo ng naturang bakuna sa pagitan ng Pilipinas at ng SII sa lalong madaling panahon.

Ang SII ay nagsusuplay ng iba’t ibang klase ng bakuna sa bansa, lalo na iyong mga ipinamahagi kaugnay sa Expanded Program for Immunization ng pamahalaan.

Kaakibat naman ng SII ang Faberco Life Sciences, Inc. para sa iba pang vaccination programs sa bansa, tulad ng Inactivated Polio vaccine, Rotavirus vaccine, at Pneumococcal Conjugate vaccine.

CONTACT US

Anchored on its mantra, “Sentro ng Katotohanan, Tapat sa Mamamayan”, Balita Central Digital complements and supports the Balita Central newspaper published bi-monthly to combat fake news and to provide the public with easy-to-digest news bits that are sourced solely from the Presidency and government agencies. 

Balita Central is under the supervision of the Bureau of Communications Services (BCS), one of the attached agencies of the Presidential Communications Operations Office (PCOO).

Launched on February 28, 2019 at the Manila Light Rail Transit System Line 2 (LRT-2) Cubao Station, Quezon City, it also aims to raise awareness among local communities about the policies, programs, and accomplishments of the Presidency. 

Through this platform, Balita Central Digital aims to reach further the online community to deliver more accurate information and communication services in order to educate the citizenry regarding national issues which would enlighten them to be engaged and be empowered in contributing to building a better nation.

Balita Central is situated at the BCS Headquarters located beside the Philippine Cancer Society along San Rafael, San Miguel, Malacañang Complex, Manila City. Its official website address is balitacentral.ph.

For inquiries and feedback, Balita Central may be contacted at editorialdesk.bcs@gmail.com.